RECRUITING

Sarcopenia Magnetic Resonance Imaging Evaluation (SUSIE)

Conditions

Study Overview

This clinical trial focuses on testing the efficacy of different digital interventions to promote re-engagement in cancer-related long-term follow-up care for adolescent and young adult (AYA) survivors of childhood cancer.

Description

The goal of the proposed research is to investigate Magnetic Resonance (MR) Fingerprinting and P-MRS (Phosphorus-31 MR Spectroscopy) imaging for characterization of skeletal muscle in heart failure patients with sarcopenia. Heart failure patients with and without sarcopenia will be scanned using MR Fingerprinting and an existing Post-exercise phosphocreatine (PCr) recovery MR imaging protocol to obtain characteristic profiles of quantitative T1, T2, and PCr recovery rate.

Official Title

Sarcopenia Characterization Using Magnetic Resonance Fingerprinting and Phosphorous Magnetic Resonance Spectroscopic Imaging Evaluation (SUSIE)

Quick Facts

Study Start:2021-04-09
Study Completion:2026-04-30
Study Type:Not specified
Phase:Not Applicable
Enrollment:Not specified
Status:RECRUITING

Study ID

NCT04869813

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Ages Eligible for Study:40 Years
Sexes Eligible for Study:ALL
Accepts Healthy Volunteers:Not specified
Standard Ages:ADULT, OLDER_ADULT
Inclusion CriteriaExclusion Criteria
  1. * Heart failure patients
  2. * Age ≥40 yrs
  3. * Stable chronic heart failure
  4. * Systolic dysfunction determined by cardiac MRI with left ventricle ejection fraction 40% or less
  5. * Healthy Volunteers
  6. * Age ≥40 yrs
  7. * No diagnosed heart failure or sarcopenia
  1. * Heart failure patients
  2. * Healthy volunteers (controls)
  3. * Advanced liver disease, advanced cancer, advanced chronic obstructive pulmonary disease
  4. * Contraindications to MRI Contraindications to MRI
  5. * Heart pacemaker/defibrillator
  6. * Electronic/implanted stimulators or devices, including deep brain stimulator, vagus nerve stimulator, bladder stimulator, spine stimulator, neurostimulators; implanted electrodes or wires
  7. * Cochlear implant or other ear implants
  8. * Implanted drug pumps (insulin, narcotic/pain medications, drugs to treat spasticity)
  9. * Programmable shunt
  10. * Aneurysm clips and coils
  11. * Stents
  12. * Filters (for example, blood clot filters)
  13. * Metal fragment in body or eye (eg, BBs, bullets, shrapnel, metal pieces or shavings)

Contacts and Locations

Study Contact

Timothy A Engelman, LPN
CONTACT
216-636-6153
engelmt@ccf.org
Wilcox D Wilcox, BA
CONTACT
216-636-6153
kirsopj@ccf.org

Principal Investigator

W. H. Wilson Tang, MD
PRINCIPAL_INVESTIGATOR
The Cleveland Clinic

Study Locations (Sites)

Cleveland Clinic
Cleveland, Ohio, 44195
United States

Collaborators and Investigators

Sponsor: The Cleveland Clinic

  • W. H. Wilson Tang, MD, PRINCIPAL_INVESTIGATOR, The Cleveland Clinic

Study Record Dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Registration Dates

Study Start Date2021-04-09
Study Completion Date2026-04-30

Study Record Updates

Study Start Date2021-04-09
Study Completion Date2026-04-30

Terms related to this study

Additional Relevant MeSH Terms

  • Sarcopenia